{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:47:50Z","timestamp":1783133270081,"version":"3.54.6"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>Histomorphologic prognostic biomarkers that can be measured using only an hematoxylin and eosin stain are very attractive because they are simple and cheap. We conceived an entirely novel biomarker of this type, the Breslow density (BD), which measures invasive melanoma cell density at the site where Breslow thickness (BT) is measured. This study assessed BD\u2019s prognostic value. In this study, BD was measured in 1329 melanoma patients. Measurement accuracy and precision was assessed using intraclass correlation coefficient (ICC). Survival was assessed with a primary end-point of melanoma-specific survival (MSS) and also overall survival and metastasis-free survival. We found that BD measurement was accurate compared with gold standard image analysis (ICC, 0.84). Precision was excellent for 3 observers with different experience (ICC, 0.93) and for an observer using only written instructions (ICC, 0.93). BD was a highly significant predictor in multivariable analysis for overall survival, MSS, and metastasis-free survival (each, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) and it explained MSS better than BT, but BT and BD together had best explanatory capability. A BD cut point of \u226565% was trained in 970 melanomas and validated in 359. This cut point showed promise as a novel way to upstage melanoma from T stage \u201ca\u201d to \u201cb.\u201d BD was combined with BT to create a targeted burden score. This was a validated as an adjunct to American Joint Committee on Cancer stage. In summary, BD can be measured accurately and precisely. It demonstrated independent prognostic value and explained MSS better than BT alone. Notably, we demonstrated ways that BD could be used with American Joint Committee on Cancer version 8 staging.<\/jats:p>","DOI":"10.1097\/pas.0000000000001034","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T21:57:05Z","timestamp":1518818225000},"page":"715-725","source":"Crossref","is-referenced-by-count":17,"title":["Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging"],"prefix":"10.1097","volume":"42","author":[{"given":"Gerald","family":"Saldanha","sequence":"first","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yarrow","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Pancholi","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Flatman","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Wee","family":"Teo","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaia","family":"Elsheik","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Nottingham University Hospitals, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"O\u2019Riordan","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bamford","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","article-title":"Analysis of trends in US melanoma incidence and mortality","volume":"153","author":"Glazer","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaad.2017.04.1126","article-title":"The new paradigm of systemic therapies for metastatic melanoma","volume":"77","author":"Volpe","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III bRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-20230922","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA: Cancer J Clin"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1253735","article-title":"The melanoma revolution: from uV carcinogenesis to a new era in therapeutics","volume":"346","author":"Lo","year":"2014","journal-title":"Science"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/his.13060","article-title":"Breslow density is a novel prognostic feature in cutaneous malignant melanoma","volume":"70","author":"Rashed","year":"2016","journal-title":"Histopathology"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol Bull"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12874-017-0336-2","article-title":"Review and evaluation of performance measures for survival prediction models in external validation settings","volume":"17","author":"Rahman","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"R19-20230922","first-page":"411","article-title":"What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models","volume":"66","author":"Babyak","year":"2004","journal-title":"Psychosom Med"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00265-010-1029-6","article-title":"AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons","volume":"65","author":"Burnham","year":"2011","journal-title":"Behav Ecol Sociobiol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour mARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-62703-727-3_13","article-title":"Construction and analysis of multi-parameter prognostic models for melanoma outcome","volume":"1102","author":"Gould-Rothberg","year":"2014","journal-title":"Methods Mol Biol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/03007995.2016.1192997","article-title":"Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients","volume":"32","author":"Berger","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma","volume":"15","author":"Clark","year":"1984","journal-title":"Hum Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12079-016-0349-3","article-title":"Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma","volume":"10","author":"Wang","year":"2016","journal-title":"J Cell Commun Signal"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0733-8635(18)30368-1","article-title":"Volume of malignant melanoma is superior to thickness as a prognostic indicator. preliminary observation","volume":"9","author":"Friedman","year":"1991","journal-title":"Dermatol Clin"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00000372-199604000-00009","article-title":"Rapid and unbiased estimation of the volume of cutaneous malignant melanoma using cavalieri\u2019s principle","volume":"18","author":"Bahmer","year":"1996","journal-title":"Am J Dermatopathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000356121","article-title":"Tumor volume as a prognostic factor in resectable malignant melanoma","volume":"228","author":"Voss","year":"2014","journal-title":"Dermatology"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:35:22Z","timestamp":1695422122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001034","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}